tbuckley/cabot-search huggingface dataset:
Abstract 19277: Late Systolic Central Hypertension as a Predictor of Incident Heart Failure: the Multi-Ethnic Study of Atherosclerosis
Authors: Julio A Chirinos, Patrick Segers, Daniel A Duprez, Lyndia Brumback, David Bluemke, Richard Kronmal, Dhananjay Vaidya, Pamela Ouyang, Raymond Townsend, David R Jacobs
Journal: Circulation (2014)

Background: Experimental studies demonstrate that high aortic pressure in late systole relative to early systole, causes greater myocardial remodeling and dysfunction, for any given absolute peak systolic pressure. Methods: We tested the hypothesis that late systolic hypertension, defined as the ratio of late (last 1/3 of systole) to early (first 2/3 of systole) pressure-time integrals (PTI) of the aortic pressure waveform, independently predicts incident heart failure (HF) in the general population. Aortic pressure waveforms were derived from a generalized transfer function applied to the radial pressure waveform recorded non-invasively from 6,124 adults. The late/early systolic PTI ratio (L/ESPTI) was assessed as a predictor of incident heart failure (HF) during median 8.5 years of follow-up. Results: The L/ESPTI was predictive of incident HF (hazard ratio per 1% increase=1.22; 95%CI=1.15-1.29; P&lt;0.0001) even after adjustment for established risk factors for HF (HR=1.23; 95%CI=1.14-1.32: P&lt;0.0001). In a multivariate model that included brachial systolic and diastolic blood pressure and other standard risk factors of HF, L/ESPTI was the modifiable factor associated with the greatest improvements in model performance. A high L/ESPTI was more predictive of HF than the presence of hypertension. After adjustment for each other and various predictors of HF, the HR associated with hypertension was 1.39 (95%CI=0.86-2.23; P=0.18) whereas the HR associated with a high L/E was 2.31 (95%CI=1.52-3.49; P&lt;0.0001). Cumulative hazard curves for HF among participants stratified according to the presence or absence of hypertension (prevalence=45%) or a high L/ESPTI (set empirically to an identical prevalence of 45% based on E/LSPTI) are shown in the figure. Conclusions: Independently of the absolute level of peak pressure, late systolic hypertension is strongly associated with incident HF in the general population.
Growth Differentiation Factor 15, a Marker of Lung Involvement in Systemic Sclerosis, Is Involved in Fibrosis Development but Is not Indispensable for Fibrosis Development
Authors: Stijn Lambrecht, Vanessa Smith, Katelijne De Wilde, Julie Coudenys, Saskia Decuman, Dieter Deforce, Filip De Keyser, Dirk Elewaut
Journal: Arthritis & Rheumatology (2013)

Transforming growth factor β superfamily members are involved in the pathogenesis of systemic sclerosis (SSc). Growth differentiation factor 15 (GDF-15) is a distant member of this family. We undertook this study to evaluate the role of GDF-15 in SSc pathogenesis.A longitudinal prospective cohort of SSc patients was screened for serum GDF-15 levels using enzyme-linked immunosorbent assay, and associations with clinical data were analyzed. In vitro stimulation experiments were performed on lung fibroblasts. The role of GDF-15 in fibrosis development in vivo was evaluated in the bleomycin lung fibrosis model in GDF-15-deficient mice.GDF-15 was measured at baseline in serum samples from 119 SSc patients. An increase in GDF-15 levels was observed in patients classified as having no skin involvement, those with limited cutaneous SSc, and those with diffuse cutaneous SSc. Moreover, baseline serum GDF-15 levels correlated strongly with disease activity and extent of organ involvement, particularly clinical symptoms of lung fibrosis, including impact on lung function at prospective followup. This was mimicked in the bleomycin model of SSc, in which animals exposed to bleomycin had elevated expression levels of GDF-15 in lung tissue. Lung fibroblasts isolated from GDF-15-deficient mice showed reduced induction of interleukin-6 and CCL2 upon bleomycin stimulation. Surprisingly, no differences in fibrosis development were observed between wild-type and GDF-15-deficient animals.An intriguing profile of serum GDF-15 levels was found in SSc patients. GDF-15 expression is induced during fibrosis development and markedly correlates with lung function impairment in this disease. The protein may participate in fibrosis initiation, but is not indispensable in the course of fibrosis development in vivo.
Abstract 4144: Genetic and epidemiology characterization of head and neck cancers by targeted sequencing
Authors: Sandra Perdomo, Luciana Reis, Devasena Anantharaman, James Mckay, Paul Brennan
Journal: Cancer Research (2014)

Abstract Oral and pharyngeal cancer, grouped together, is the sixth most common cancer in the world. The annual estimated incidence is around 275,000 for oral and 130,300 for pharyngeal cancers excluding nasopharynx, two-thirds of these cases occurring in developing countries. The principal objective of this work was to investigate the somatic genetic changes that influence the risk of head and neck cancer occurrence and outcome, and how they interact with environmental and host factors: HPV infection, alcohol and Smoking. We selected 205 paired samples diagnosed as head and neck SCC included in two multicenter studies in Europe and Brazil: ARCAGE, a multi center case- control study, conducted between 2002-2005 involving 10 countries across Europe and the Gencapo case- control study in the state of Sao Paulo from 2001 to 2010. Targeted sequencing was performed independently on both germline DNA and the tumor material using the PGM™ System at an average depth of 250X.Sequencing included the entire coding region of 5 of the most frequently mutated genes in Head and Neck cancer: TP53, NOTCH1, CDKN2A, CASP8, and PTEN. HPV status was achieved by capsid protein serology and DNA genotyping. Statistical tests were carried out in the R statistical programming environment or using STATA statistic software. Kaplan-Meier analysis was used to determine overall survival. Statistically significant differences in exposure status were found between both series of patients with more prevalent cases of former and current both smokers and alcohol drinkers in Brazil(p=0.001). 76% and 63% of the patients in each series had at least 1 mutation and there were no significant differences in the percentage of mutations found. Most of the mutations were found in TP53 (60%) and NOTCH1 (18%). Smoking status was significantly associated to TP53 mutations (p=0.015). Positive serology for HPV16 E6 oncoprotein was associated to Oropharyngeal tumors all of which lack TP53 mutations. When comparing the survival of patients according to the mutational profile we found a reduction in overall survival for those patients carrying mutations in TP53 (p=0.002) and CDKN2A (p=0.001). Combined molecular profiling and exposure data can be a resource to assess the role of lifestyle habits on prognosis, and will help to identify early markers of survival for head and neck cancer patients. Citation Format: Sandra Perdomo, Luciana Reis, Devasena Anantharaman, James Mckay, Paul Brennan. Genetic and epidemiology characterization of head and neck cancers by targeted sequencing. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 4144. doi:10.1158/1538-7445.AM2014-4144
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
Authors: T Bernal, P Martínez-Camblor, J Sánchez-García, R de Paz, E Luño, B Nomdedeu, M T Ardanaz, C Pedro, M L Amigo, B Xicoy, C del Cañizo, M Tormo, J Bargay, D Valcárcel, S Brunet, L Benlloch, G Sanz
Journal: Leukemia (2015)
Risky Research Rewarded
Authors: Tracy Hampton
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Neomycin, Its Nature and Practical Application.
Authors: John M. Adams
Journal: Annals of Internal Medicine (1958)

This book on neomycin is an excellent compilation f information on an antibiotic that has gained a permanent place among the useful therapeutic agents of today. Edited by Dr. Waksman and his associates, comprising a total of 35 contributors, no aspect of the story of neomycin is untouched from its brief history of less than ten years since its discovery in 1949 to its everyday use in clinical medicine at the present time.  Neomycin has found a permanent place in the therapy of man and animals, and because it is not readily absorbed from the gastrointestinal tract it has become an ideal intestinal antiseptic agent as well as being highly useful in the treatment of many infectious diseases.
Does teledermoscopy validate teledermatology for triage of skin lesions?
Authors: S.M. Halpern
Journal: British Journal of Dermatology (2010)

Journal Article Does teledermoscopy validate teledermatology for triage of skin lesions? Get access S.M. Halpern S.M. Halpern Department of Dermatology Medway Maritime Hospital, Gillingham Kent ME7 5NY, U.K. E‐mail: saul.halpern@medway.nhs.uk Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 162, Issue 4, 1 April 2010, Pages 709–710, https://doi.org/10.1111/j.1365-2133.2010.09739.x Published: 01 April 2010
The beta subunit of the high-affinity IgE receptor, a candidate for atopic dermatitis, is not imprinted
Authors: S. Yotsumoto, T. Kanzaki, M.S.H. Ko
Journal: British Journal of Dermatology (2000)

Journal Article The beta subunit of the high‐affinity IgE receptor, a candidate for atopic dermatitis, is not imprinted Get access S. Yotsumoto, S. Yotsumoto Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, 5047 Gullen Mall, Detroit, MI 48202, U.S.A.Department of Dermatology, Faculty of Medicine, Kagoshima University, 8‐35‐1 Sakuragaoka, Kagoshima 890‐8520, Japan Search for other works by this author on: Oxford Academic Google Scholar T. Kanzaki, T. Kanzaki Department of Dermatology, Faculty of Medicine, Kagoshima University, 8‐35‐1 Sakuragaoka, Kagoshima 890‐8520, Japan Search for other works by this author on: Oxford Academic Google Scholar M.S.H. Ko M.S.H. Ko Center for Molecular Medicine and Genetics, Wayne State University School of Medicine, 5047 Gullen Mall, Detroit, MI 48202, U.S.A.Developmental Genomics and Ageing Section, Laboratory of Genetics, National Institute on Ageing, National Institutes of Health, 333 Cassell Drive, Suite 4000, Baltimore, MD 21224‐6825, U.S.A. E‐mail: kom@grc.nia.nih.gov Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 142, Issue 2, 1 February 2000, Pages 370–371, https://doi.org/10.1046/j.1365-2133.2000.03312.x Published: 01 February 2000
Abstract 3795: Cabozantinib affects multiple signaling pathways in glioblastoma and is effective in a subset of xenograft tumors
Authors: Ana C. deCarvalho, Kimberly Arnold, Claudius Mueller, Emanuel F. Petricoin, Laila M. Poisson, Tom Mikkelsen
Journal: Cancer Research (2014)

Abstract Background: Glioblastoma (GBM) is the most common and aggressive form of brain tumor characterized by poor prognosis and high recurrence rate. Several new targeted agents are being considered for the adjuvant treatment of GBMs. Cabozantinib, a multi-kinase currently in clinical trials for several malignancies, including glioblastoma, targets c-Met and VEGFR2 receptors, as well as Ret, Kit, Flt-1/3/4, Tie2, and AXL. Our goal is to first evaluate sensitivity and molecular response of patient-derived GBM cancer stem cells (CSCs) to XL184 in vitro. Anti-tumor efficacy of cabozantinib as a single agent and in combination with the DNA-alkylating agent temozolomide (TMZ) in orthotopic xenografts was then evaluated. Methods: Neurospheres enriched in CSCs were cultured from resected GBM tumors. Sensitivity to cabozantinib was determined in vitro. Cells were treated (IC40) in triplicate, and cell lysates were analyzed by reverse phase protein microarrays. GBM CSCs were implanted intracranially into nude mice. Cabozantinib was administered by oral gavage at a dose of 60mg/kg for 4 weeks (5 days/week) as a single agent or in combination with 40mg/kg TMZ. Tumor growth and response to treatment were monitored by non-invasive in vivo biolumiescent imaging (BLI) using the Xenogen IVIS System (Caliper Life Sciences), and overall survival. Results: Sensitivity to cabozantinib treatment varied for the different GBM CSCs. From 70 proteins and phosphoproteins measured, 29 distributed among several signaling pathways were significantly altered after treatment in both resistant and sensitive GBM CSCs. Cabozantinib single agent treatment reduced GBM tumor growth and increased mouse survival in two xenograft lines. Cabozantinib monotherapy reduced tumor size, as measured by BLI, but had no significant effect on overall survival for another xenograft line, however, the combination treatment resulted in sensitization of these xenografts to TMZ treatment. Conclusion: The use of multi-kinase inhibitors is a promising strategy for GBMs, and given the range of responses, identifying predictive biomarkers, though challenging, will be invaluable for patient stratification. Citation Format: Ana C. deCarvalho, Kimberly Arnold, Claudius Mueller, Emanuel F. Petricoin, Laila M. Poisson, Tom Mikkelsen. Cabozantinib affects multiple signaling pathways in glioblastoma and is effective in a subset of xenograft tumors. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3795. doi:10.1158/1538-7445.AM2014-3795
Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials
Authors: W. van den Brink
Journal: BMJ (2003)

<h3>Abstract</h3> <b>Objective</b> To determine whether supervised medical prescription of heroin can successfully treat addicts who do not sufficiently benefit from methadone maintenance treatment. <b>Design</b> Two open label randomised controlled trials. <b>Setting</b> Methadone maintenance programmes in six cities in the Netherlands. <b>Participants</b> 549 heroin addicts. <b>Interventions</b> Inhalable heroin (n = 375) or injectable heroin (n = 174) prescribed over 12 months. Heroin (maximum 1000 mg per day) plus methadone (maximum 150 mg per day) compared with methadone alone (maximum 150 mg per day). Psychosocial treatment was offered throughout. <b>Main outcome measures</b> Dichotomous, multidomain response index, including validated indicators of physical health, mental status, and social functioning. <b>Results</b> Adherence was excellent with 12 month outcome data available for 94% of the randomised participants. With intention to treat analysis, 12 month treatment with heroin plus methadone was significantly more effective than treatment with methadone alone in the trial of inhalable heroin (response rate 49.7% <i>v</i> 26.9%; difference 22.8%, 95% confidence interval 11.0% to 34.6%) and in the trial of injectable heroin (55.5% <i>v</i> 31.2%; difference 24.3%, 9.6% to 39.0%). Discontinuation of the coprescribed heroin resulted in a rapid deterioration in 82% (94/115) of those who responded to the coprescribed heroin. The incidence of serious adverse events was similar across treatment conditions. <b>Conclusions</b> Supervised coprescription of heroin is feasible, more effective, and probably as safe as methadone alone in reducing the many physical, mental, and social problems of treatment resistant heroin addicts.
Myofibroblasts in Murine Cutaneous Fibrosis Originate From Adiponectin‐Positive Intradermal Progenitors
Authors: Roberta Goncalves Marangoni, Benjamin D. Korman, Jun Wei, Tammara A. Wood, Lauren V. Graham, Michael L. Whitfield, Philipp E. Scherer, Warren G. Tourtellotte, John Varga
Journal: Arthritis & Rheumatology (2014)

Objective Accumulation of myofibroblasts in fibrotic skin is a hallmark of systemic sclerosis (SSc; scleroderma), but the origins of these cells remain unknown. Because loss of intradermal adipose tissue is a consistent feature of cutaneous fibrosis, we sought to examine the hypothesis that myofibroblasts populating fibrotic dermis derive from adipocytic progenitors. Methods We performed genetic fate mapping studies to investigate the loss of intradermal adipose tissue and its potential role in fibrosis in mice with bleomycin‐induced scleroderma. Modulation of adipocytic phenotypes ex vivo was investigated in adipose tissue–derived cells in culture. Results A striking loss of intradermal adipose tissue and its replacement with fibrous tissue were consistently observed in mice with bleomycin‐induced fibrosis. Loss of adipose tissue and a decline in the expression of canonical adipogenic markers in lesional skin preceded the onset of dermal fibrosis and expression of fibrogenic markers. Ex vivo, subcutaneous adipocytes were driven by transforming growth factor β to preferentially undergo fibrogenic differentiation. Cell fate mapping studies in mice with the adiponectin promoter–driven Cre recombinase transgenic construct indicated that adiponectin‐positive progenitors that are normally confined to the intradermal adipose tissue compartment were distributed throughout the lesional dermis over time, lost their adipocytic markers, and expressed myofibroblast markers in bleomycin‐treated mice. Conclusion These observations establish a novel link between intradermal adipose tissue loss and dermal fibrosis and demonstrate that adiponectin‐positive intradermal progenitors give rise to dermal myofibroblasts. Adipose tissue loss and adipocyte–myofibroblast transition might be primary events in the pathogenesis of cutaneous fibrosis that represent novel potential targets for therapeutic intervention.
MEDICINE AND THE EDUCATIONAL PROCESS
Authors: L A KIMPTON
Journal: Annals of Internal Medicine (1954)

Article1 October 1954MEDICINE AND THE EDUCATIONAL PROCESSLAWRENCE A. KIMPTONLAWRENCE A. KIMPTONSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-41-4-816 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptMr. Toastmaster, Members of the American College of Physicians: I feel honored to be asked to address the top of a profession for which I have great respect and admiration. Lest I be misunderstood, perhaps I should add that, like a happy marriage, I love you in sickness and in health.The General Chairman of your Thirty-fifth Annual Session, a most engaging fellow, made the error of saying that I could talk about anything I chose. For some reason, the complete layman with such an open invitation is drawn irresistibly to speak about a learned profession; and with an ignorance... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Chicago, Illinois*Address at the Annual Banquet of The American College of Physicians, Chicago, Illinois, April 8, 1954. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 1954Volume 41, Issue 4Page: 816-819 ePublished: 1 December 2008 Issue Published: 1 October 1954 PDF downloadLoading ...
The presence of a FLT3 mutation in AML adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the MRC AML 10 and 12 trials.
Authors: P. D. Kottaridis, R. E. Gale, M. E. Frew, G. Harrison, S. E. Langabeer, A. A. Belton, H. Walker, K. Wheatley, D. T. Bowen, Alan Kenneth Burnett, A. H. Goldstone, D. C. Linch
Journal: Blood (2000)
Abstract 12961: Prognostic Significance of Post-Procedural Sustained Ventricular Tachycardia or Fibrillation in Patients Undergoing Primary Percutaneous Coronary Intervention: Insights from the HORIZONS AMI Trial
Authors: Rajendra H Mehta, Jonathan P Piccini, James T Tcheng, Martin Fahy, Roxana Mehran, Gregg W Stone
Journal: Circulation (2010)

Background: Few studies that have evaluated the prognostic significance of sustained ventricular tachycardia or fibrillation (VT/VF) in patients (pts) undergoing primary percutaneous coronary inter...
Model-Based Assessment of Right Ventricular Arterial Coupling During Septic Shock – Results With a Porcine Model
Authors: Thomas Desaive, Bernard Lambermont, N. Janssen, Alexandre Ghuysen, Philippe Kolh, Pierre Dauby, C. Starfinger, C. E. Hann, G. M. Shaw, G. Chase
Journal: Intensive Care Medicine (2008)
Failure to Thrive
Authors: Floyd Skloot
Journal: JAMA (2000)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal